tirzepatide and general anesthesia Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society for Perioperative Assessment Quality Improvement (SPAQI) multidisciplinary consensus statement MHRA warns of pulmonary aspiration

The hidden GLP-1 connection Here is something fascinating that most articles about this combination miss entirely

(68), which reported that sweet taste receptor antagonism with lactisole reduced GLP-1 and PYY secretion but had no effect on CCK release, highlighting pathway-specific effects

In rare cases, it may lead to pancreatitis

Tirzepatide es un medicamento inyectable aprobado por la FDA para el tratamiento de la diabetes tipo 2 (bajo el nombre comercial Mounjaro) y para el manejo del peso en adultos con obesidad (IMC 30 kg/m) o sobrepeso (IMC 27 kg/m) con al menos una comorbilidad relacionada con el peso (como Zepbound)

Interestingly, preliminary studies in animals suggest tirzepatide might even shrink certain tumours, including breast cancer, but these findings are still very early and not yet applicable to humans

This may cause nausea, bloating, or even vomiting